Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077976 | 0.91 | CA1 (0.36) | CA1CA2CA4CA7CA9 | |
| SCHEMBL13240714 | 0.81 | PGR (0.38) | — | |
| SCHEMBL10121047 | 0.79 | CA1 (0.36) | CA1CA2CA4CA7CA9 | |
| SCHEMBL10144348 | 0.77 | HTR2B (0.32) | CA1CA2CA4CA7CA9 | |
| SCHEMBL10144412 | 0.76 | PBRM1 (0.35) | BCL2MCL1ESR1ESR2STK17B | |
| SCHEMBL13219394 | 0.72 | CA1 (0.37) | CA1CA2CA4CA7CA9 | |
| SCHEMBL13219506 | 0.71 | CA1 (0.36) | CA1CA2CA4CA7CA9 | |
| SCHEMBL13078221 | 0.71 | CA1 (0.36) | CA1CA2CA4CA7CA9 | |
| SCHEMBL10121055 | 0.71 | PBRM1 (0.32) | CA1CA2CA4CA7CA9 | |
| SCHEMBL12128946 | 0.70 | TDP2 (0.34) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, CYP1B1 | CA1 2525/4885CA2 2555/4885CA4 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.